Evidence from credible sources supports the statement as accurate. Learn more in Methodology.
Formal MFN pricing agreements exist between the federal government and the named pharmaceutical manufacturers that set or commit to prices aligned with the lowest in other developed nations.
The White House and related administration releases explicitly state that they secured "Most‑Favored‑Nation" (MFN) pricing agreements with multiple pharmaceutical manufacturers and describe those deals as aligning U.S. prices with the lowest prices in other developed nations. Independent news outlets (Reuters, AP, CNN) and company press releases confirm that the administration announced MFN-style deals with a set of large drugmakers (e.g., Dec. 19, 2025 announcements) and that discounted pricing would be offered through TrumpRx.gov and made available to state Medicaid programs. Verdict: True — the administration did say it secured MFN pricing agreements to align U.S. prices with the lowest in other developed nations; however, reporting and company statements show the agreements are limited in scope (specific companies, Medicaid access and direct-to-consumer cash pricing) and implementation details/impacts vary, so the administration’s broad claim about fully "ensuring" nationwide alignment is overstated.